Media Articles Related to Stelara (Ustekinumab)
Psoriasis: Physical Activity May Reduce Risk, Disease Course
Source: Medscape Dermatology Headlines [2014.08.26]
Exercise appeared to decrease the risk of developing psoriasis as well as the severity of disease in a cross-sectional study.
Medscape Medical News
Health Tip: Soothing Psoriasis on the Feet
Source: MedicineNet Psoriasis Specialty [2014.08.20]
Title: Health Tip: Soothing Psoriasis on the Feet
Category: Health News
Created: 8/20/2014 7:35:00 AM
Last Editorial Review: 8/20/2014 12:00:00 AM
Psoriasis Ups Risk of Cancer, Serious Infection
Source: MedPage Today Dermatology [2014.08.08]
CHICAGO (MedPage Today) -- Rates of malignancy and infection-related hospitalization among patients with psoriasis outpaced national averages, irrespective of therapy in most cases.
Psoriasis: Screen for Fatty Liver Before MTX?
Source: MedPage Today Dermatology [2014.08.08]
CHICAGO (MedPage Today) -- What began as a case of chronic plaque psoriasis has evolved into consideration of routine testing for nonalcoholic steatohepatitis before initiating methotrexate, according to a British study.
Psoriasis Foundation drives efforts to cure psoriasis and psoriatic arthritis with new strategic plan
Source: Arthritis / Rheumatology News From Medical News Today [2014.07.11]
National Psoriasis Foundation will double the number of researchers studying psoriasis and psoriatic arthritis while also cutting in half the number of people who say these chronic conditions are a...
Published Studies Related to Stelara (Ustekinumab)
An update on the long-term safety experience of ustekinumab: results from the
psoriasis clinical development program with up to four years of follow-up. 
severe psoriasis treated for up to four years... CONCLUSION: The safety profile of long-term ustekinumab treatment with up to four
Long-term safety experience of ustekinumab in patients with moderate to severe
psoriasis (Part II of II): results from analyses of infections and malignancy
from pooled phase II and III clinical trials. 
exposed up to 3 years... CONCLUSIONS: The emerging safety profile of ustekinumab remains favorable and
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. 
This phase 2/3, double-blind, placebo-controlled study was designed to assess the
safety and efficacy of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis. Overall, 158 patients were randomized to receive
ustekinumab 45 or 90 mg at weeks 0, 4, and every 12 weeks, or placebo with
cross-over to ustekinumab at week 12...
Long-term safety experience of ustekinumab in patients with moderate-to-severe
psoriasis (Part I of II): results from analyses of general safety parameters from
pooled Phase 2 and 3 clinical trials. 
ustekinumab through 3 years of treatment... CONCLUSIONS: The safety profile of continued ustekinumab exposure through up to 3
Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]
Background Different biological agents are used for the treatment of psoriasis. Previous data have shown adalimumab to be the most efficient drug in terms of cost-efficacy... The robustness of this finding was confirmed by sensitivity analysis.
Clinical Trials Related to Stelara (Ustekinumab)
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis [Recruiting]
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of
ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis [Recruiting]
This study will provide data on sasety and efficacy of Ustekinumab in patients suffering
from Palmo-Plantar Pustular Psoriasis (PPPP) or Palmo-Plantar Pustulosis(PPP)
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) [Recruiting]
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients
with moderate to severe psoriasis.
TRANSIT - A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate [Recruiting]
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who
receive ustekinumab following an inadequate response to methotrexate therapy. The study
will provide information for doctors on how to manage the transfer from methotrexate to the
biologic agent ustekinumab. The study is designed to compare two methods of transferring
patients from methotrexate to ustekinumab. The two methods being compared are
discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation
of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients
with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.
Reports of Suspected Stelara (Ustekinumab) Side Effects
Myocardial Infarction (71),
Drug Ineffective (67),
OFF Label USE (41),
Drug Dose Omission (34),
Psoriatic Arthropathy (34), more >>